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Implication for health policy/practice/research/medical education:
In a cross-sectional study, 60 hemodialysis patients older than 18 years and the dialysis duration longer than three months were 
enrolled. Echocardiography was done and was repeated in all of the patients. From the total of cases 37 were male and 23 female. 
After 12 months left ventricular ejection fraction (LVEF) decreased significantly, however there was no significant difference 
between other echocardiographic findings at the beginning and after 12 months. Decrease in LVEF over time in hemodialysis 
patients may be due to negative effect of uremia on cardiac function, so it seems that periodical cardiac evaluation of these patients 
is essential and beneficial.
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Introduction: Cardiovascular disease is the most common cause of morbidity and mortality 
in hemodialysis patients. 
Objectives: The aim of this study was to detect echocardiographic abnormality in the 
beginning and after 12-month follow-up in the hemodialysis patients.
Patients and Methods: In a cross-sectional study, 60 hemodialysis patients older than 18 
years and the dialysis duration longer than three months were enrolled. At the beginning of 
the study, echocardiography was done and after 12 months was repeated in all of the patients 
by the same cardiologist. At the end of the study, data were analyzed using SPSS software 
(version 19).
Results: From the total of cases 37 were male and 23 female. At the beginning of the study, 
mitral regurgitation, tricuspid regurgitation and aortic insufficiency were found in 54, 47 and 
11 patients respectively. After 12 months left ventricular ejection fraction (LVEF) decreased 
significantly, however there was no significant difference between other echocardiographic 
findings at the beginning and after 12 months.
Conclusion: Decrease in LVEF over time in hemodialysis patients may be due to negative 
effect of uremia on cardiac function, so it seems that periodical cardiac evaluation of these 
patients is essential and beneficial.
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Introduction
Cardiovascular disease is responsible for about 60% of 
mortality rate in hemodialysis patients that is 30 times 
more prevalent than in general population (1-2). Some 
predisposing factors to sudden death in these patients in-
clude left ventricular hypertrophy (LVH), electrolyte shifts 
in hemodialysis session and abnormalities in myocardial 
ultrastructure and function (3). Different cardiovascular 
diseases, such as LVH, coronary artery diseases, conges-
tive heart failure, and hypertension are commonly seen 
in these patients (4,5). In addition, calcification of cardiac 
valves is common and can cause valvular and annular 
thickening which in turn could lead to valvular stenosis 
or regurgitation (6). Some predisposing factors of cardiac 
disorders in dialysis patients are secondary hyperparathy-
roidism, long-term hypertension, anemia, large inter-di-
alytic fluid gains, uremic internal milieu, and presence of 
vascular grafts and arteriovenous fistulae (7,8). Left ven-
tricular dysfunction and LVH are poor prognostic factors 
and increase mortality in hemodialysis patients (9,10). 
National Kidney Foundation recommend baseline and 
routine echocardiographic follow-up for end-stage renal 
disease (ESRD) patients (11). In chronic kidney disease 
patients, there is a stepwise increase in LVH and reduc-
tion in left ventricular ejection fraction (LVEF) with pro-
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initiation of dialysis left ventricular mass index may be 
decreased compared to prior to dialysis probably due to 
relief of venous congestion (13). 
Objectives
There is little research on change of echocardiographic 
findings during a long time follow-up, so the aim of the 
present study is to evaluate echocardiographic changes 
during 12 months in hemodialysis patients.
Patients and Methods
Study population
In this cross-sectional study, 60 hemodialysis patients 
older than 18 years and the dialysis duration longer than 
three months were enrolled.
Data collection
At the beginning of the study echocardiography was done 
in all of the patients and repeated by the same cardiolo-
gist after 12 months. Echocardiography was performed 
after the dialysis session using Vivid S6 Machine (USA). 
The patients were on hemodialysis, by Fresenius digital 
machine (4008B, Germany) and Gambro digital machine 
(AK95 and AK96, Sweden), 2 to 3 times per week. Dialysis 
duration was 4 to 4.5 hours per session with blood flow 
(QB) of 250 to 350 ml/min and dialysate flow (QD) of 500 
ml/min. Ultrafiltration was based on the patient’s condi-
tion (about 1 to 3 liter each time); however, at the end of 
dialysis session the patients were in their dry weight.
The used buffer was bicarbonate powder and the type of 
filters were intermediate and high efficient polysulfide 
membrane of R6 or R7 (SOHA, Fresenius Company). For 
measurement of urea reduction ratio (URR) and KT/V in 
the patients, serum BUN and Cr were checked in the same 
laboratory before and after hemodialysis session. To un-
dertake echocardiography, an informed consent was con-
fidentially filled out by the patients. In the echocardiogra-
phy in this study, LVEF, LVH, pulmonary artery pressure, 
and valvular disorders were evaluated.
Exclusion criteria
Exclusion criteria were antiarrhythmic drugs consump-
tion, history of cardiac disease such as arrhythmia, heart 
block or congestive heart failure.
Ethical issues
1) The research followed the tenets of the Declaration 
of Helsinki; 2) informed consent was obtained, and they 
were free to leave the study at any time and 3) the research 
was approved by the ethical committee of Shahrekord 
University of Medical Sciences.
Statistical analysis
At the end of this study, data were analyzed using SPSS 
software (version 19). P value less than 0.05 was con-
sidered as significant. Pearson correlation coefficient, 
two-independent samples t test and analysis of variance 
(ANOVA) were used for statistical analysis. 
Results
From the total of 60 patients, 37 were male and 23 female. 
The causes of renal failure were diabetes mellitus, hyper-
tension, hereditary kidney disease, chronic glomerulone-
phritis, and unknown in 26, 15, 8, 5 and 6 patients, re-
spectively. Mean age of the patients was 56.15 ± 14.6 years. 
Mean body mass indexes (post dialysis) and duration of 
dialysis were 21.77 ± 3.6 kg/m2 and 4.25 ± 3.24 years re-
spectively (Table 1). Mean URR in men and women was 
68.14 ± 9.34 and 68.22 ± 3.88 respectively; however, KT/V 
was 1.45 ± 0.17 and 1.49 ± 0.16 in men and women, respec-
tively. In the beginning of the study LVH was seen in 23 
(38.3%) of the patients based on septal thickness greater 
than 10 mm, and ST-T change in14 patients (23.3%). In 
echocardiography, mitral regurgitation (MR), tricuspid 
regurgitation (TR) and aortic insufficiency (AI) were 
found in 54, 47 and 11 patients, respectively. In the sec-
ond echocardiography (after 12 months), in 38 patients 
(63.3%) LVEF did not change, in 18 patients (30%) de-
creased and in 4 patients (6.7%) increased, so LVEF de-
creased significantly compared to the beginning of the 
study by paired t test (P = 0.007). At the end of the study, 
LVEF was not correlated with MR (P = 0.14), AI (P = 0.11) 
or TR (P = 0.39). However, there was no significant dif-
ference among other abovementioned echocardiographic 
findings at the beginning of the study and after 12 months 
in the studied patients (Table 2).
Discussion
Chronic effect of hemodialysis on left ventricular (LV) 
function has not been well understood. Our results 
showed that LVEF of the patients decreased significantly 
after 12 months despite the acceptable adequacy of hemo-
dialysis. Valvular disorders and LVH also were common 
even in the patients without obvious cardiac disease but 
there was no difference between these findings at the be-
ginning and end of this study.
In hemodialysis patients, due to chronic hypertension, 
volume overload, and high cardiac load (because of pres-
ence of an AVF and chronic anemia), LV diastolic and 
systolic dysfunction may occur and ejection fraction 
eventually decreases (14). There are a few studies about 
the echocardiographic changes over time. For example, 
Duran et al in 22 newly diagnosed cases of ESRD showed 
that LV systolic functions, LV diameters, LV mass index, 
left atrium size, and RV diastolic functions did not sta-
tistically change after long-term hemodialysis treatment 
(15). In our study decrease in LV function over time in the 
patients may be due to negative effect of uremia on heart 
Table 1. Demographic and laboratory findings of patients
Characteristic Age (year) Body weight (kg) BMI (kg/m2) Duration of dialysis (year) Dialysis/week
Value (Mean ± SD) 56.15 ± 14.6 62.13 ± 14.54 21.77 ± 3.6 4.25 ± 3.24 2.9 ± 0.3
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muscle fibers (16). In hemodialysis patients, chronic vol-
ume overload, LVH, chronic anemia and electrolyte im-
balance are predisposing factors of cardiomyopathy and 
decrease in LVEF (17). Discrepancy between the results 
of Duran et al and our study is probably due to difference 
in the scale of the study. The majority of other researches 
focused on the changes during the dialysis session. In Wu
 et al study on hemodialysis patients, where the evalua-
tion was done by three dimensional echocardiography, 
there was no significant change in LVEF before and after 
hemodialysis session (18). LVH in hemodialysis patients 
is common and is caused due to chronic hypertension, 
anemia and other factors such as hyperparathyroidism. 
Prevalence of LVH in hemodialysis patients was reported 
42% to 75% based on duration of renal failure (19). In our 
study LVH was found in 38.3% of the patients and did not 
change after 12 months. LVH and diastolic dysfunction 
are more common in hemodialysis patients with diabetes 
mellitus. Accordingly, Hung et al in a study on 101 he-
modialysis patients with normal systolic function found 
that diabetes mellitus patients had advanced LV diastolic 
dysfunction compared to non-diabetic patients (20). In 
addition to LVH, diastolic dysfunction may be developed 
due to regional wall motion abnormalities (RWMA). For 
example Assa et al showed that hemodialysis could induce 
RWMA in a significant proportion of patients, and these 
abnormalities may lead to increased mortality rate (21).
Also, our results showed that there were valvular disor-
ders in a considerable number of the patients. In some 
other studies, similar to our results, valvular disorders in 
hemodialysis patients were common. Risk factors of val-
vular disorders in hemodialysis patients are calcification 
of heart valves and other factors such as anemia, LVH and 
hypertension (22-24).
Conclusion
Our results showed that LVEF decreased over time in 
hemodialysis patients, probably due to negative effect of 
renal failure and hemodialysis on cardiac function. So, it 
seems that annually cardiac evaluation and follow-up of 
these patients are essential and beneficial.
Limitations of the study
The study had some limitations such as small sample size 
and short duration of follow-up, thus we recommend to 
conduct of similar studies as multi-centric with longer du-
ration of follow-up.
Table 2. Echocardiographic findings of the patients before and 
after the study
Echocardiographic variable Value P
EF1 (%) 51.92 ± 4.60 0.007
EF2 (%) 50.42 ± 5.30
PAP1 (mm Hg) 33.83 ± 13.25 0.1
PAP2 (mm Hg) 31.58 ± 12.63
Septal thickness 1(mm) 13.23 ± 1.60 0.08
Septal thickness 2 (mm) 12.97 ± 1.50
Abbreviations: EF, Ejection fraction; PAP, Pulmonary arterial pressure.
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